Apelin-13 deteriorates hypertension in rats after damage of the vascular endothelium by ADMA

Canadian Journal of Physiology and Pharmacology

Volumn 91, Issue 9, 2013, Pages 708-714

  Han, Xue ^a   Zhang, Dong Iiang ^a   Yin, Dao Xin ^a   Zhang, Qi Dong ^a   Liu, Wen Hu ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Apelin; Asymmetric dimethylarginine; Endothelium; Hypertension; Rat; Vasoconstriction; Vasodilatation

Indexed keywords

APELIN; APELIN 13; MYOSIN LIGHT CHAIN; N(G),N(G) DIMETHYLARGININE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SYSTOLIC BLOOD PRESSURE; TRANSMISSION ELECTRON MICROSCOPY; VASCULAR ENDOTHELIUM;

ANIMALS; ARGININE; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HYPERTENSION; INJECTIONS, INTRAVENOUS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MYOSIN LIGHT CHAINS; NITRIC OXIDE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VASOCONSTRICTION; VASODILATION; VON WILLEBRAND FACTOR;

EID: 84883297234     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2013-0046     Document Type: Article

References (28)

1. Abedini, S., Meinitzer, A., Holme, I., Marz, W., Weihrauch, G., Fellstrom, B., Jardine, A., and Holdaas, H. 2010. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int. 77(1): 44-50. doi:10.1038/ki.2009.382.
2. Cheng, X., Cheng, X.S., and Pang, C.C. 2003. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur. J. Pharmacol. 470(3): 171-175. doi:10.1016/S0014-2999(03)01821-l.
3. De Gennaro Colonna, V., Bonomo, S., Ferrario, P., Bianchi, M., Berti, M., Guazzi, M., Manfredi, B., Muller, E.E., Berti, F., and Rossoni, G. 2007. Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats. Eur. J. Pharmacol. 557(2-3): 178-185. doi:10.1016/j.ejphar.2006.11.034.
4. Fliser, D., Kronenberg, F., Kielstein, J.T., Morath, C, Bode-Boger, S.M., Haller, H., and Ritz, E. 2005. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J. Am. Soc. Neph-rol. 16(8): 2456-2461. doi:10.1681/ASN.2005020179.
5. Hasegawa, K., Wakino, S., Tatematsu, S., Yoshioka, K., Homma, K., Sugano, N., Kimoto, M., Hayashi, K., and Itoh, H. 2007. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimeth-ylarginie dimethylaminohydrolase 2. Circ. Res. 101(2): e2-e10. doi:10.1161/CIRCRESAHA.107.156901.
6. Hashimoto, T., Kihara, M., Ishida, J., Imai, N., Yoshida, S., Toya, Y., Fukamizu, A., Kitamura, H., and Umemura, S. 2006. Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 26(6): 1267-1272. doi:10.1161/01.ATV.0000218841.39828.91.
7. Hus-Citharel, A., Bouby, N., Frugiere, A., Bodineau, L., Gase, J.M., and Llorens-Cortes, C. 2008. Effect of apelin on glomerular hemodynamic function in the rat kidney. Kidney Int. 74(4): 486-494. doi:10.1038/ki.2008.199.
8. Ishida, J., Hashimoto, T., Hashimoto, Y., Sugaya, T., Matsuzaki, H., Yamamoto, R., Shiota, N., Okunishi, H., Kihara, M., Umemura, S., Sugiyama, F., Yagami, K., Kasuya, Y., Mochizuki, N., and Fukamizu, A. 2004. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J. Biol. Chem. 279(25): 26274-26279. doi:10.1074/jbc. M404149200.
9. Jiang, D.J., Jia, S.J., Dai, Z., and Li, Y.J. 2006. Asymmetric dimethylarginine induces apoptosis via p38 MAPK/caspase-3-dependent signaling pathway in endothelial cells. J. Mol. Cell. Cardiol. 40(4): 529-539. doi:10.1016/j.yjmcc. 2006.01.021.
10. Katugampola, S.D., Maguire, J.J., Matthewson, S.R., and Davenport, A.P. 2001. [(125)I]-(Pyr(l))apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br. J. Pharmacol. 132(6): 1255-1260. doi:10.1038/sj.bjp.0703939.
11. Losano, G.A. 2005. On the cardiovascular activity of apelin. Cardiovasc. Res. 65(1): 8-9. doi:10.1016/j.cardiores.2004.10.027.
12. Maguire, J.J., Kleinz, M.J., Pitkin, S.L., and Davenport, A.P. [Pyrl]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension, 54(3): 598-604. doi:10. 1161/HYPERTENSIONAHA.109.134619.
13. Moody, W.E., Edwards, N.C., Madhani, M., Chue, CD., Steeds, R.P., Ferro, C.J., and Townend, J.N. 2012. Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association. Atherosclerosis, 223(1): 86-94. doi:10.1016/j.atherosclerosis.2012.01.043.
14. Pitkin, S.L., Maguire, J.J., Kuc, R.E., and Davenport, A.P. 2010. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. Br. J. Pharmacol. 160(7): 1785-1795. doi:10.1111/j.l476-5381.2010.00821.x.
15. Ravani, P., Tripepi, G., Malberti, F., Testa, S., Mallamaci, F., and Zoccali, C. 2005. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J. Am. Soc. Nephrol. 16(8): 2449-2455. doi:10.1681/ASN.2005010076.
16. Reaux, A., De Mota, N., Skultetyova, I., Lenkei, Z., El Messari, S., Gallatz, K., Corvol, P., Palkovits, M., and Llorens-Cortes, C. 2001. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J. Neurochem. 77(4): 1085-1096. doi:10.1046/j.l471-4159.2001.00320.x.
17. Rudic, R.D., Shesely, E.G., Maeda, N., Smithies, O., Segal, S.S., and Sessa, W.C. 1998. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J. Clin. Invest. 101(4): 731-736. doi:10.1172/JCI1699.
18. Siekmeier, R., Grammer, T., and Marz, W. 2008. Roles of oxidants, nitric oxide, and asymmetric dimethylarginine in endothelial function. J. Cardiovasc. Pharmacol. Ther. 13(4): 279-297. doi:10.1177/1074248408326488.
19. Suda, O., Tsutsui, M., Morishita, T., Tasaki, H., Ueno, S., Nakata, S., Tsujimoto, T., Toyohira, Y., Hayashida, Y., Sasaguri, Y., Ueta, Y., Nakashima, Y., and Yanagihara, N. 2004. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler. Thromb. Vase. Biol. 24(9): 1682-1688. doi:10.1161/01ATV.0000136656.26019.6e.
20. Tatemoto, K., Takayama, K., Zou, M.X., Kumaki, I., Zhang, W., Kumano, K., and Fujimiya, M. 2001. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul. Pept. 99(2-3): 87-92. doi:10.1016/S0167-0115(01)00236-1.
21. Testa, A., Spoto, B., Tripepi, G., Mallamaci, F., Malatino, L, Fatuzzo, P., Maas, R., Boeger, R., and Zoccali, C. 2005. The GLU298ASP variant of nitric oxide syn-thase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. J. Hypertens. 23(10): 1825-1830. doi:10.1097/01.hjh.0000182528.59687.dl.
22. Thomas, S.R., Witting, P.K., and Drummond, G.R. 2008. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid. Redox Signal. 10(10): 1713-1765. doi:10.1089/ars.2008. 2027.
23. Vallance, P., and Leiper, J. 2005. Asymmetric dimethylarginine and kidney disease-marker or mediator. J. Am. Soc. Nephrol. 16(8): 2254-2256. doi:10. 1681/ASN.2005050539.
24. Wang, D., Strandgaard, S., Borresen, MX., Luo, Z., Connors, S.G., Yan, Q., and Wilcox, C.S. 2008. Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 51(2): 184-191. doi:10.1053/j.ajkd.2007.09.020.
25. Wang, L.Y., Zhang, D.L., Zheng, J.F., Zhang, Y., Zhang, Q.D., and Liu, W.H. 2011. Apelin-13 passes through the ADMA-damaged endothelial barrier and acts on vascular smooth muscle cells. Peptides, 32(12): 2436-2443. doi:10.1016/j. peptides.2011.10.001.
26. Wojciak-Stothard, B., Torondel, B., Tsang, L.Y., Fleming, I., Fisslthaler, B., Leiper, J.M., and Vallance, P. 2007. The ADMA/DDAH pathway is a critical regulator of endothelial cell motility. J. Cell Sci. 120(6): 929-942. doi:10.1242/ jcs.002212.
27. Wu-Wong, J.R. 2008. Endothelial dysfunction and chronic kidney disease: treatment options. Curr. Opin. Investig. Drugs, 9(9): 970-982.
28. Zhang, D.L., Liao, H., Wei, Y.Y., Zhang, Y., Zhang, Q.D., and Wang, Z.G. 2009. Elevation of serum apelin-13 is positively correlated with ADMA in patients on maintenance hemodialysis. Clin. Nephrol. 71(4): 405-412. doi:10.5414/ CNP71405.